Based on the results of present study, and highlighted issues in previous reports, the utility of RUNX1 and ASXL1 mutations in stratifying intermediate-risk AML is debated and further investigation of HCT with these mutations is warranted. This evidence concerns the gene ASXL1 and acute myeloid leukemia.